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CASE REPORT
Metoclopramide-induced parkinsonism due to bilateral basal ganglia and brain stem 
involvement in a patient with laryngeal carcinoma
Larinks kanserli hastada beyin sapı ve bazal ganglion tutulumu ile birlikte metoklopramidin 
indüklediği parkinsonizm
Ali İnal1, Ertuğrul Uzar2, Muhammed Ali Kaplan1, Mehmet Küçüköner1, Zuhat Urakcı1, Faysal Ekici3, 
Abdurrahman Işıkdoğan1
ÖZET
Metoklopramid gibi antiemetik ilaçlara bağlı parkinsonizm 
ve bazal ganglion tutulumu nadirdir. Ancak, bilateral bazal 
ganglion ve beyin sapı tutulumu ilaca bağlı parkinsonizm 
hastalarında henüz bildirilmemiştir.
Larinks kanseri olan 52 yaşındaki erkek hasta dosetaksel, 
sisplatin ve 5-fluorourasil (DCF) kemoterapisi ile tedavi 
edildi. Kemoterapinin ilk küründen 15 gün sonra şiddetli 
bulantı ve kusma şikayeti nedeniyle metoklopramid ve-
rildi. 
Metoklopramid tedavisinin 6. gününde parkinsonizm be-
lirtileri gözlendi. Çekilen serebral MRG’de bilateral bazal 
ganglionlarda ve beyin sapında tutulum saptandı. Metok-
lopramid tedavisi derhal kesilerek ve ağızdan biperiden 
başlandı. Parkinsonizm bulguları bir ay sonra gerçekleşti-
rilen kontrol muayenesinde neredeyse tamamen düzeldi. 
Hastaya  daha  sonraki  kemoterapi  tedavilerinde  metok-
lopramid verilmedi. Üç ay sonra çekilen serebral MRG’de 
lezyonlar tamamen düzeldi.
Kemoterapi ile tedavi edilen larinks kanserli hastada be-
yin sapı ve bazal ganglion tutulumu ile birlikte metoklop-
ramidin  indüklediği  parkinsonizm  çok  nadir  görülen  bir 
durumdur. Klinik ve radyolojik iyileşme neden olan ilacın 
kesilmesi ve biperiden tedavisi ile gözlenmiştir.
Anahtar kelimeler:  Parkinsonizm,  metoklopramid,  la-
rinks kanseri
ABSTRACT
Parkinsonism and basal ganglion involvement due to an-
tiemetic drugs, such as metoclopramide, is rarely encoun-
tered. However, bilateral basal ganglia and brain stem 
involvement has not yet been reported in patients with 
drug-induced Parkinsonism. 
A 52-year-old male patient with laryngeal carcinoma was 
treated with docetaxel, cisplatin, and 5-fluorouracil (DCF) 
chemotherapy. Because of severe nausea and vomiting 
15  days  after  the  first  course  of  chemotherapy,  meto-
clopramide  was  administered.  Parkinsonism  symptoms 
were observed on the 6th day of metoclopramide therapy. 
Cerebral MRI revealed bilateral basal ganglia and brain 
stem involvement. Metoclopramide therapy was promptly 
discontinued and oral biperiden was commenced. Par-
kinsonism  findings  almost  completely  improved  on  his 
control examination performed after one month. He was 
not given metoclopramide during further chemotherapy 
courses. Cerebral MRI taken after three months revealed 
that the lesions have completely relieved.
This is an extremely rare case of metoclopramide-induced 
parkinsonism together with brain stem and basal ganglion 
involvement in a patient with laryngeal carcinoma treated 
by chemotherapy. The clinical and radiological improve-
ment was observed with the cessation of the causative 
drug and biperiden therapy. J Clin Exp Invest 2012; 3(4): 
536-538
Key words:  Parkinsonism,  metoclopramide,  laryngeal 
carcinoma
INTRODUCTION
The  drug-induced  parkinsonism  accounts  for  ap-
proximately  2.7%  of  these  patients.1  Metoclo-
pramide  is  a  dopamine  receptor  antagonist  and 
may occasionally cause extrapyramidal side effects 
due to its dopaminergic antagonistic effect.2,3 Par-
kinsonism and basal ganglion involvement due to 
antiemetic drugs, such as metoclopramide, is rarely 
reported,4 whereas bilateral basal ganglia and brain 
stem involvement has not yet been reported until 
now on the brain MRI of the patients with drug-in-İnal et al. Metoclopramide-induced parkinsonism 537
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duced Parkinsonism. We present the first case of 
metoclopramide-induced  Parkinsonism  together 
with brain stem and basal ganglion involvement in 
a patient with laryngeal carcinoma treated with che-
motherapy.
CASE REPORT
A 52-year-old male patient with locally advanced la-
ryngeal carcinoma. He started to receive a chemo-
therapy regimen consisted of docetaxel, cisplatin, 
and 5-fluorouracil (DCF). He was admitted to our 
clinic because of severe nausea and vomiting 15 
days after the first course of chemotherapy. Fluid re-
placement and metoclopramide (oral, 20 mg daily) 
were commenced to control dehydration and vom-
iting. Tremor in the hands, dysarthria, mask face, 
restlessness, irritability and limited movement de-
veloped in the patient on the 6th day of metoclo-
pramide therapy. Neurologic examination revealed 
akathisia, sialorrhea, hypomimia, bradykinesia, par-
kinsonian gait and tremor in all extremities. Drug-in-
duced parkinsonism and akathisia (extrapyramidal 
side effect) were diagnosed for the patient by the 
consultation with the neurology department. Com-
plete blood count, electrolytes, anti DNA, Vitamin 
B12, folic acid and thyroid functions were within the 
normal  ranges.  On  his  cerebral  MRI,  T1  hypoin-
tense and T2 hyperintense signal changes were de-
termined in the bilateral basal ganglia, including pu-
tamen, globus pallidus and the head of the caudate 
nucleus, as well as in the mesencephalon area, in-
cluding nucleus ruber and nucleus ruber (fig.1a,1b). 
Laryngeal cancer metastasis was not considered, 
because the contrast substance was not uptaken 
by the lesions on the contrast-enhanced MRI of the 
cerebrum. 
Metoclopramide therapy was immediately dis-
continued and oral biperiden was started with the 
dose of 2 mg three times daily. Parkinsonism symp-
toms slightly improved on the 3rd day of biperiden 
therapy. Neurologic examination performed 15 days 
later revealed bilateral tremor in the hands of the 
patient has disappeared and limited movement and 
dysarthria have considerably regressed. The par-
kinsonian findings almost completely improved on 
control examination after one month. The lesions in 
the basal ganglion were absent on the follow-up MRI 
of the cerebrum. However, T1 hypointense and T2 
hyperintense changes were observed on the brain 
stem lesions, including nucleus ruber (Fig.1c,1d). 
Biperiden  therapy  was  gradually  decreased  and 
discontinued. DCF course was repeated for three 
times. Metoclopramide was not preferred as an an-
tiemetic in this patient. Parkinsonism complaints did 
not recur, and the patient has been free of any as-
sociated symptoms.
Figure 1, a; Axial T2 MRI revealed T2 hyperintense signal changes in the caudate nucleus, globus pallidus and puta-
men, b; as well as in the mesencephalon region, including nucleus ruber and the periphery of nucleus rubber, c; The 
follow-up cerebral T2 axial revealed the increased signal to disappear in the caudate nucleus, globus pallidus and puta-
men, d; however, the increased signal persisted in the mesencephalon region. 
DISCUSSION
Symptoms due to the damage of the extrapyramidal 
system, such as parkinsonism, acute dystonic re-
action, akathisia, motor tics, myoclonus and tardive 
dyskinesia, may be seen. One of these symptoms 
may occur alone, or they may present together.4 It 
has been put forward that the pathogenesis of drug-
induced Parkinsonism results from the imbalance 
between acetylcholine and dopamine in the central 
nervous system (CNS). Extrapyramidal side effects 
commonly appear 24 hours after metoclopramide is 
started and generally disappears 24 hours after dis-
continuation. Extrapyramidal side effects quite rare-
ly persist for weeks or months.3 In this case, dysar-
thria, irritability, desire to move continuously, slow-
ing down in walking, and tremor were developed 
after  24  hours  following  metoclopramide  given  in 
order to prevent nausea. Metoclopramide-induced 
Parkinsonism and akathisia, rather than idiopathic İnal et al. Metoclopramide-induced parkinsonism 538
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Parkinson’s disease, was considered owing to the 
fact that he had no history of Parkinson’s disease 
and that his complaints have begun bilaterally and 
acute. No other reason was found that could lead 
to parkinsonism and akathisia. It has been reported 
that certain chemotherapeutic agents cause parkin-
sonism.5  Parkinsonism  symptoms  were  not  pres-
ent in this case during the first course of anticancer 
therapy. Following the second course of anticancer 
therapy, parkinsonism was seen at the same time 
with metoclopramide. After the relief of parkinson-
ism, it did not recur following the third course of anti-
cancer therapy. Moreover, metoclopramide-induced 
parkinsonism  has  been  reported  more  commonly 
than  anticancer  drug-induced  parkinsonism.1-4,6 
Consequently,  Parkinsonism  and  akathisia  were 
not attributed to the anticancer therapy. Moreover, 
they  gradually  disappeared  with  the  cessation  of 
metoclopramide.  Metoclopramide-induced  Parkin-
sonism and akathisia together with the involvement 
of basal ganglion, thalamus and brain stem in can-
cer patients has not yet been reported. However, in 
Parkinsonism caused by toxic substances, such as 
carbon monoxide and manganese, globus pallidus, 
substantia nigra, nucleus ruber and brain stem can 
also be involved. Parkinsonism may be developed 
due to the involvement of the extrapyramidal sys-
tem, including brain stem, substantia nigra, striatum 
and thalamus.7-10
The cerebral MRI performed in the subacute 
period revealed bilateral involvement of the puta-
men, as well as globus pallidus, the head of the 
caudate nucleus, substantia nigra from the mesen-
cephalon to pons, and nucleus rubber in this case. 
This shows that the effect of metoclopramide on the 
extrapyramidal pathways is similar with that of man-
ganese and carbon monoxide intoxication. Parkin-
sonism complaints of the patient decreased within 
one  month  with  chemotherapy.  Caudate  nucleus, 
globus pallidus and putamen lesions of the present 
case disappeared on his control MRI performed af-
ter three months. Although the Parkinsonism signs 
have disappeared, nucleus ruber lesions persisted 
at the mesencephalon level. 
Metoclopramide-induced  Parkinsonism  and 
akathisia can be seen rarely. Putamen, globus pal-
lidus, the head of caudate nucleus and nucleus ru-
ber may also be affected in such patients. In a case 
of metoclopramide-induced Parkinsonism, cerebral 
MRI  should  be  performed  to  visualize  the  major 
damage in the extrapyramidal system. 
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